Key facts
- This page summarizes Ross Moat's Form 4 filing for Kiniksa Pharmaceuticals International, plc (KNSA).
- 29 reported transactions and 9 derivative rows are listed below.
- Accepted by SEC: 03 Nov 2026, 18:27.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Options Exercise
Options Exercise
Options Exercise
Options Exercise
Options Exercise
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Options Exercise
Options Exercise
Options Exercise
Sale
Sale
Sale
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Options Exercise
Options Exercise
Options Exercise
Options Exercise
Options Exercise
Options Exercise
Options Exercise
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 29, 2026.
Footnote F2
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $91.36 to $92.35. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Footnote F3
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $92.36 to $93.31. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Footnote F4
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $93.37 to $94.36. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Footnote F5
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $94.375 to $95.215. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Footnote F6
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $95.485 to $96.405. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Footnote F7
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $96.54 to $97.48. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Footnote F8
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $97.60 to $98.30. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Footnote F9
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $90.64 to $91.63. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Footnote F10
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $91.64 to $92.525. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Footnote F11
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $92.732 to $93.725. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Footnote F12
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $93.94 to $94.135. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Footnote F13
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023.
Footnote F14
The option is fully vested and exercisable.
Footnote F15
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.
Footnote F16
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024.
Footnote F17
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2025.